Truvestments Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Truvestments Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.43K	Hold	199	–	–	﹤0.01%	899
2025 Q4	$5.32K	Hold	199	–	–	﹤0.01%	799
2025 Q3	$4.25K	Hold	199	–	–	﹤0.01%	849
2025 Q2	$4.29K	Hold	199	–	–	﹤0.01%	750
2025 Q1	$3.31K	Hold	199	–	–	﹤0.01%	800
2024 Q4	$3.65K	Hold	199	–	–	﹤0.01%	743
2024 Q3	$3.06K	Buy	+199	New	+$3.32K	﹤0.01%	747
2024 Q2	–	Sell	-199	Closed	-$3.68K	–	223
2024 Q1	$3.68K	Hold	199	–	–	﹤0.01%	574
2023 Q4	$6.23K	Hold	199	–	–	﹤0.01%	568
2023 Q3	$4.15K	Hold	199	–	–	﹤0.01%	527
2023 Q2	$4.77K	Hold	199	–	–	﹤0.01%	532
2023 Q1	$3.75K	Hold	199	–	–	﹤0.01%	536
2022 Q4	$3.17K	Sell	199 -82	-29%	-$1.28K	﹤0.01%	639
2022 Q3	$5K	Hold	281	–	–	﹤0.01%	461
2022 Q2	$4K	Buy	+281	New	+$5.24K	﹤0.01%	487
2022 Q1	–	Sell	-281	Closed	-$7K	–	181
2021 Q4	$7K	Hold	281	–	–	﹤0.01%	434
2021 Q3	$5K	Hold	281	–	–	﹤0.01%	445
2021 Q2	$7K	Hold	281	–	–	﹤0.01%	419
2021 Q1	$7K	Hold	281	–	–	﹤0.01%	477
2020 Q4	$15K	Buy	+281	New	+$13.9K	0.01%	385
2020 Q3	–	Sell	-281	Closed	-$13K	–	313
2020 Q2	$13K	Buy	+281	New	+$13.5K	0.01%	350
2019 Q4	–	Sell	-492	Closed	-$18K	–	142
2019 Q3	$18K	Sell	492 -30	-6%	-$910	0.01%	419
2019 Q2	$14K	Hold	522	–	–	0.01%	476
2019 Q1	$14K	Buy	+522	New	+$12.2K	0.01%	456
2018 Q3	$11K	Buy	+550	New	+$8.65K	0.01%	611

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Truvestments Capital's ACAD Position: Q1 2026 in Review

Truvestments Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 199 shares worth $4.43K. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Truvestments Capital first reported a position in ACAD in Q3 2018 and has held it in 25 quarters since. The position peaked at $18K in Q3 2019. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Truvestments Capital held 199 shares of Acadia Pharmaceuticals worth $4.43K as of Q1 2026.
Truvestments Capital left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #899 holding.
Truvestments Capital first reported a position in Acadia Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
Truvestments Capital's Acadia Pharmaceuticals position peaked at $18K in Q3 2019.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.